产品详情
查看大图

  • 产品名称：VascularEndothelialGrowthFactor(VEGF)(AA27-191)(Active)Protein

  • 产品型号：
  • 产品厂商：ACROBiosystems
  • 产品文档：
你添加了1件商品 查看购物车
简单介绍：
VascularEndothelialGrowthFactor(VEGF)(AA27-191)(Active)Protein
详情介绍：
Brand ActiveMax®
Characteristics This protein carries no "tag". The protein has a calculated MW of 19 kDa (monomer). As a result of glycosylation, the protein migrates as 24 kDa (monomer) under reducing (R) condition, and 43-50 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE).
Purity >98 % as determined by SDS-PAGE.
Sterility 0.22 μm filtered
Endotoxin Level Less than 1.0 EU per μg by the LAL method.
Grade HPLC verified
ProductDetails: Biological Activity Comment Biological Activity: The bio-activity was determined by dose-dependent stimulation of the proliferation of HUVEC cells. The ED50 < 5 ng/mL, corresponding to a specific activity of >2X105 Unit/mg. Measured by its ability to bind human rhVEGFR1 (Cat# VE1-H5220) in the SPR assay (Biacore 2000) with an estimated KD of 0.1nM. Measured by its ability to bind human rhVEGFR2 (Cat# KDR-H5227) in the SPR assay (Biacore 2000) with an estimated KD< 50nM.
Background VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.
Molecular Weight 19 kDa (monomer)
NCBI Accession NP_001020539
UniProt P15692
Research Area Signaling, Receptors, Immunology, Cytokines, Growth Factors, Inflammation
Restrictions For Research Use only
Format Lyophilized
Reconstitution Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Buffer PBS, pH 7.4
Handling Advice Avoid repeated freeze-thaw cycles.
Storage -20 °C
Storage Comment No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
Supplier Images
SDS-PAGE (SDS) image for Vascular Endothelial Growth Factor (VEGF) (AA 27-191) (Active) Protein (ABIN2181903) Human VEGF165 on SDS-PAGE under reducing (R) and no-reducing (NR) conditions. The gel...
Binding Studies (Bind) image for Vascular Endothelial Growth Factor (VEGF) (AA 27-191) (Active) Protein (ABIN2181903) Immobilized Human VEGF165 with a linear range of 3-50 ng/mL.
Binding Studies (Bind) image for Vascular Endothelial Growth Factor (VEGF) (AA 27-191) (Active) Protein (ABIN2181903) Immobilized Human VEGF165 at 2 μg/mL can bind VEGFR2/R3-Fc with a linear range of 0...
Background publications Takahashi, Shibuya: "The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions." in: Clinical science (London, England : 1979), Vol. 109, Issue 3, pp. 227-41, 2005 (PubMed).

Robinson, Stringer: "The splice variants of vascular endothelial growth factor (VEGF) and their receptors." in: Journal of cell science, Vol. 114, Issue Pt 5, pp. 853-65, 2001 (PubMed).

Neufeld, Cohen, Gengrinovitch, Poltorak: "Vascular endothelial growth factor (VEGF) and its receptors." in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 13, Issue 1, pp. 9-22, 1999 (PubMed).